近日，维立志博发布公告表示，将与Dianthus Therapeutics,Inc.签订全球独家许可协议，据此，公司与 Dianthus达成全球独家合作伙伴关系，共同推进临床前资产及新型抗BDCA2-TACI双特异性融合蛋白 LBL-047，LBL-047已获美国新药临床试验(IND)许可及中国内地IND受理。 （维立志博公告） (编辑：林辰) 根据全球独家许可协议，Dianthus将获得在大中华区以外地区研发、生产及商业化LBL-047的全球独家 权益。根据全球独家许可协议，公司将获得最高38百万美元的首付款及潜在近期里程碑付款及最高10亿 美元的潜在临床开发、监管及商业化里程碑付款。公司将有权获得大中华区以外地区净销售额的分级特 许权使用费，费率从中个位数至低双位数不等。 公司将藉此机会与在开发变革性严重自身免疫疾病疗法领域具有公认领导地位和深厚专长的Dianthus达 成合作。公司认为签订全球独家许可协议将加强本集团推进创新候选药物进入临床阶段以解决自身免疫 疾病的承诺，并符合公司及其股东的整体最佳利益。 ...

Core Viewpoint - The company has entered into a global exclusive licensing agreement with Dianthus Therapeutics to advance the development of a novel dual-specificity fusion protein, LBL-047, aimed at treating severe autoimmune diseases [1][2] Group 1: Licensing Agreement Details - The agreement grants Dianthus exclusive rights to research, develop, and commercialize LBL-047 outside of Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [1] - The company will receive an upfront payment of up to $38 million, along with potential milestone payments totaling up to $1 billion related to clinical development, regulatory, and commercialization achievements [1] - The company will also earn tiered royalties on net sales outside of Greater China, with rates ranging from single digits to low double digits [1] Group 2: Strategic Importance - The collaboration with Dianthus, recognized for its leadership and expertise in developing transformative therapies for severe autoimmune diseases, is expected to enhance the company's commitment to advancing innovative drug candidates into clinical stages [2] - The signing of the global exclusive licensing agreement aligns with the overall best interests of the company and its shareholders [2]